Pharmacokinetics of a Novel Amphetamine Extended-Release Orally Disintegrating Tablet in Children with Attention-Deficit/Hyperactivity Disorder

201620 citationsJournal Article

Authors

Jeffrey G. Stark · Worldwide Clinical Trials (United States)

Dorothy Engelking · Neoleukin Therapeutics (United States)

Russ McMahen · Neoleukin Therapeutics (United States)

Carolyn R. Sikes · Neoleukin Therapeutics (United States)

Abstract

AMP XR-ODT, a novel formulation that does not require swallowing an intact tablet or capsule, was well tolerated and demonstrated a PK profile consistent with once-daily dosing in children with ADHD.

Topics & Keywords

Attention Deficit Hyperactivity Disorder Pharmaceutical studies and practices Bipolar Disorder and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Child and Adolescent Psychopharmacology

Volume 27, Issue 3, pp. 216-222

DOI: 10.1089/cap.2016.0119

Field-Weighted Citation Impact: 2.49